Wall Street Journal

Moderna Stock Shoots Up on $2.3 Billion Patent Settlement

The vaccine maker agreed to a settlement regarding litigation over its Covid-19 shot.Hannah Beier/Reuters Moderna shares surged 16% Wednesday to their highest level since 2024 after the company agreed ...
New York Post

‘Universal’ nasal spray vax could protect against COVID, flu — and even allergies

Flu and COVID and allergies, oh my! With a record-breaking flu season still underway — and spring allergies just around the corner — you may find your medicine cabinet packed to the brim with ...
The Motley Fool

Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear

Moderna helped to rapidly create vaccines for COVID-19, leading to a financial windfall. But those vaccine sales have waned, and so has the company's top line. There are opportunities ahead for ...
New York Post

Spread the word, not the virus: Get measles vax

Don’t mess with measles. That should be a PSA to all parents in California and America: MMR (Measles, Mumps and Rubella) is not a vaccine to skip. Health officials in Sacramento recently issued a ...
NBC News

A school district’s battle between vax rules and budgets

Here’s the Scoop: The St. Louis School District shows there is a delicate balance between enforcing vaccination requirements in schools and facing the consequences of doing so. NBC News’ Stephanie ...
Boston Herald

Dear Abby: I’m expecting, and relatives won’t vax

Dear Abby: I am having a baby in five months. My doctor is recommending that anyone who visits the baby in the first three months be up to date on vaccines (Tdap, flu, COVID and RSV, if age 60-plus).
MarketWatch

Moderna’s stock rallies as settlement of a patent dispute clears vaccine pipeline

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...
The News Journal

Moderna will pay up to $2.25B to end COVID vaccine patent fight

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...
Wall Street Journal

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Moderna MRNA-1.55%decrease; red down pointing triangle will pay $950 million to settle patent litigation by Arbutus Biopharma and Genevant Sciences GmbH. The vaccine maker said Tuesday that, as part ...
The Motley Fool

Moderna's Ups and Downs: Here's What You Need to Know Before Investing.

Moderna has faced good and bad times in recent years. Most recently, the FDA refused to review Moderna’s flu candidate -- then reversed course. The company has had its ups -- the approval of its ...
Seeking Alpha

Moderna gains as Arbutus/ Genevant settlement removes major financial risk

Moderna (MRNA) shares continued to rise in the premarket on Wednesday as analysts argued that the company’s agreement to resolve a patent dispute with Arbutus Biopharma (ABUS) and the Roivant unit ...